No abstract

No abstract

No abstract

BackgroundPublication retraction is a mechanism to preserve the scientific literature against publications that contain seriously flawed or erroneous data, redundant publication, plagiarism, unethical research, and other features that compromise the integrity of science. An increase in the occurrence of retractions in recent years has been reported. Nevertheless, there is scarce information on this topic concerning publications in dentistry and related specialties. Thus, this study aimed to investigate retracted papers published in dental journals.MethodsData collection included an exploratory search in PubMed and a specific search in SCImago Journal Rank indexed journals, complemented by the cases reported on the Retraction Watch website and in PubMed. All 167 dental journals included in SCImago were searched for identification of retracted articles up to March 2016. The selected retracted articles and their corresponding retraction notices were recorded and assessed for classification according to the reason for retraction and other additional information.ResultsForty of the 167 journals scrutinised at SCImago (23.9%) had at least one retracted article, and four additional journals were identified from the Retraction Watch website. A total of 72 retracted found were retracted for the reasons: redundant publication (20.8%), plagiarism (18.1%), misconduct (13.8%), overlap (13.6%) and honest error (9.7%). Higher number of retractions were reported in those journals with cites/doc <2.0—n = 49 (74.2%). The types of studies were mainly laboratory studies (34.7%), case reports (22.2%) and review articles (13.9%).ConclusionsThe approach to ethical problems in papers published in dental scientific journals is still incipient; retractions were mostly due to the authors’ malpractice and were more frequently related to journals with less impact.Electronic supplementary materialThe online version of this article (doi:10.1186/s13104-017-2576-y) contains supplementary material, which is available to authorized users.

No abstract

No abstract

No abstract

Cancer is a complex disease which includes many pathologies featuring abnormal growth of healthy cells, invasion and metastization. Cellular uncontrolled growth increases the amount of abnormal cells, these cells reach the blood stream and other healthy tissues giving rise to secondary tumors. Even though great progresses have been made in understanding cancer aetiology and in the development of new anticancer drugs, cancer still remains one of the leading causes of death worldwide. Most common cancers include breast cancer, lung cancer, colorectal cancer and brain cancer. Conventional chemotherapeutics have proven to be inefficient in cancer treatment due to lack of specificity and poor drug accumulation in tumors. In addition, they cause severe side effects. Available treatments must be prolonged on time to achieve some therapeutic effect; however, this often leads to the development of multidrug resistance by tumor cells. Nanotechnology platforms are, therefore, being exploited as potential alternatives. Nanosystems have been reported to target and deliver the drug in situ to selectively kill cancer cells, decreasing toxicity on healthy organs and tissues as well as side effects. Furthermore, some nanosystems have been reported to overcome tumor resistance, at least to some extent. Over the years several nanosystems have been proposed to diagnose and treat cancers, such as dendrimers, polymeric micelles, superparamagnetic iron oxide cores, gold nanoparticles, liposomes and other lipid nanoparticles. Due to their small size and biocompatibility, they can reach the target site without being detected by the immune system and suffer cellular uptake or deliver the drug in the tumor vicinity.